[1] Gulbins E, Li PL. Physiological and pathophysiological as-pects of ceramide[J]. Am J Physiol Regul Integr Comp Physiol, 2006, 290(1):R11-26.
[2] Huitema K, van den Dikkenberg J, Brouwers JF, et al. I-dentification of a family of animal sphingomyelin synthases[J]. EMBO J, 2004, 23(1):33-44.
[3] Hussain MM, Jin W, Jiang XC. Mechanisms involved in cel-lular ceramide homeostasis[J]. Nutr Metab (Lond), 2012, 9(1):71-77.
[4] Liu J, Zhang H, Li Z, et al. Sphingomyelin synthase 2is one of the determinants for plasma and liver sphingomyelin levels in mice[J]. Arterioscler Thromb Vasc Biol, 2009, 29(6):850-856.
[5] Li Z, Fan Y, Liu J, et al. Impact of sphingomyelin synthase 1deficiency on sphingolipid metabolism and atherosclerosis in mice[J]. Arterioscler Thromb Vasc Biol, 2012, 32(7):1577-1584.
[6] Haus JM, Kashyap SR, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2diabetes and corre-late with the severity of insulin resistance[J]. Diabetes, 2009, 58(2):337-343.
[7] Mari M, Fernandez-Checa JC. Sphingolipid signalling and liver diseases[J]. Liver Int, 2007, 27(4):440-450.
[8] Bienias K, Fiedorowicz A, Sadowska A, et al. Regulation of sphingomyelin metabolism[J]. Pharmacol Rep, 2016, 68(3):570-581.
[9] He X, Huang Y, Li B, et al. Deregulation of sphingolipid metabolism in Alzheimer's disease[J]. Neurobiol Aging, 2010, 31(3):398-408.
[10] Lang PA, Schenck M, Nicolay JP, et al. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide[J]. Nat Med, 2007, 13(2):164-170.
[11] Mielke MM, Bandaru VV, Haughey NJ, et al. Serum ce-ramides increase the risk of Alzheimer disease:the Women's Health and Aging Study Ⅱ[J]. Neurology, 2012, 79(7):633-641.
[12] Liu J, Huan C, Chakraborty M, et al. Macrophage sphin-gomyelin synthase 2deficiency decreases atherosclerosis in mice[J]. Circ Res, 2009, 105(3):295-303.
[13] Fan Y, Shi F, Liu J, et al. Selective reduction in the sphin-gomyelin content of atherogenic lipoproteins inhibits their re-tention in murine aortas and the subsequent development of atherosclerosis[J]. Arterioscler Thromb Vasc Biol, 2010, 30(11):2114-2120.
[14] Jiang XC, Liu J. Sphingolipid metabolism and atherosclerosis[J]. Handb Exp Pharmacol, 2013(216):133-146.
[15] Li Z, Zhang H, Liu J, et al. Reducing plasma membrane sphingomyelin increases insulin sensitivity[J]. Mol Cell Bi-ol, 2011, 31(20):4205-4218.
[16] 李亚, 张亚楠, 陈亚静, 等. GDNF在慢性应激和老化致小鼠行为与认知损伤中的作用[J]. 中国应用生理学杂志, 2013, 29(1):52-56.
[17] Fabelo N, Martin V, Marin R, et al. Altered lipid composi-tion in cortical lipid rafts occurs at early stages of sporadic Alzheimer's disease and facilitates APP/BACE1 interactions[J]. Neurobiol Aging, 2014, 35(8):1801-1812. |
